Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Drugs

Alemtuzumab Product Approval Information - Licensing Action 5/7/01

Proper name: Alemtuzumab
Tradename: Campath
Manufacturer: Millennium and ILEX Partners, LP, Cambridge, MA , License #1289
Indication for Use: Treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy
Approval Date: 5/7/2001
Type of submission: Biologics license application

 


Approval Letter (PDF)

Label (PDF)

Page Last Updated: 09/30/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English